Next Article in Journal
Explain Again: Why Are We Vaccinating Young Children against COVID-19?
Previous Article in Journal
Forensic Analysis of COVID-19 Data from 198 Countries Two Years after the Pandemic Outbreak
 
 
Article

Immunogenicity and Reactogenicity of CoronaVac: A Cohort Study

1
Department of Internal Medicine, Faculty of Medicine and Health Sciences, Universitas Warmadewa, Bali 80239, Indonesia
2
Eijkman Institute for Molecular Biology, Jakarta 10430, Indonesia
3
Faculty of Medicine and Health Sciences, Universitas Warmadewa, Bali 80239, Indonesia
4
Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, University of Udayana, Bali 80232, Indonesia
*
Author to whom correspondence should be addressed.
Academic Editor: Marc Desforges
COVID 2022, 2(4), 485-491; https://doi.org/10.3390/covid2040035
Received: 10 January 2022 / Revised: 28 March 2022 / Accepted: 4 April 2022 / Published: 6 April 2022
The ongoing COVID-19 pandemic remained a major public health concern despite a large-scale deployment of vaccines. One of the vaccines is CoronaVac, an inactivated vaccine. The efficacy of the vaccine was estimated at 50.7–83.5% in clinical trials. However, the real-world efficacy often differed. This study described CoronaVac post-vaccination reactogenicity and immunogenicity. Serum was collected on days 0, 28, 56 and 84 from participants who received CoronaVac in March–May 2021. Anti-SARS-CoV-2 Spike receptor binding domain was measured using an Elecsys® quantitative assay. Participants were interviewed for adverse events (AEs) one week after vaccination. Reported AEs were fatigue, fever, runny nose, headache, muscle pain, pain at injection site, and paresthesia. Females reported more incidents than males. However, the frequency was similar between immunologically naïve and pre-immune participants. In the naïve group, the antibody titer was 61.7 ± 84.2 U/mL (mean ± SD) on day 28 and increased to 99.3 ± 91.9 U/mL on day 56. The titer peaked on day 56 across all age groups, but a reduction of 18.0–26.3% was observed on day 84. A titer-boosting effect was observed in pre-immune participants with a baseline titer of 139.0 ± 101.0 U/mL, which increased to 206.7 ± 77.4 U/mL on day 28, and remained steady until day 84. Hence, CoronaVac elicited an antibody response in naïve and pre-immune participants, with mild AEs. View Full-Text
Keywords: CoronaVac; inactivated vaccine; SARS-CoV-2; spike RBD CoronaVac; inactivated vaccine; SARS-CoV-2; spike RBD
MDPI and ACS Style

Masyeni, S.; Johar, E.; Budhitresna, A.A.G.; Mahardika, N.; Dewi, N.R.K.; Widiana, I.G.R.; Yudhaputri, F.A.; Myint, K.S.A. Immunogenicity and Reactogenicity of CoronaVac: A Cohort Study. COVID 2022, 2, 485-491. https://doi.org/10.3390/covid2040035

AMA Style

Masyeni S, Johar E, Budhitresna AAG, Mahardika N, Dewi NRK, Widiana IGR, Yudhaputri FA, Myint KSA. Immunogenicity and Reactogenicity of CoronaVac: A Cohort Study. COVID. 2022; 2(4):485-491. https://doi.org/10.3390/covid2040035

Chicago/Turabian Style

Masyeni, Sri, Edison Johar, Anak Agung Gede Budhitresna, Nyoman Mahardika, Nyoman Ratna Kartika Dewi, I Gde Raka Widiana, Frilasita Aisyah Yudhaputri, and Khin Saw Aye Myint. 2022. "Immunogenicity and Reactogenicity of CoronaVac: A Cohort Study" COVID 2, no. 4: 485-491. https://doi.org/10.3390/covid2040035

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop